

**Sirolimus Market Size, Share & Trends Analysis Report By Strength (5mg, 1mg, 2mg, 1mg/mL), By Application (Organ Transplant Rejection, Sirolimus Catheter Device, Sirolimus Coated Balloons, Others), By Drug Class (mTOR Inhibitors, Selective Immunosuppressants), By Dosage (Injection, Tablet, Others), By Route of Administration (Oral, Intravenous, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031**

Market Report | 2024-03-19 | 0 pages | Straits Research

**AVAILABLE LICENSES:**

- Single User License \$4500.00
- Global Site License \$5500.00

**Report description:**

**Sirolimus Market Analysis and Insights**

The Sirolimus Market size is anticipated to reach USD 296.3 Million in 2022 and it is projected to reach USD 471.6 Million by 2031, growing at a CAGR of 5.3% during the forecast period.

The Global Sirolimus Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Sirolimus Market growth, Size report provides a comprehensive analysis of the Pharmaceuticals industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

**Research Methodology**

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Experts, Sirolimus Market includes major suppliers & Independent Consultants among others.

#### Global Market Scope and Sirolimus Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Sirolimus Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

#### Sirolimus Market Country Level Analysis

The Global Sirolimus Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Sirolimus Market share and status of critical industries is included in the report, covering Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

#### Top Players in Sirolimus Market

Some of the other major highlights of the demand for Sirolimus Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Sirolimus Market during the forecast period.

Accord Healthcare (US)

Apotex Inc. (Canada)

and Amneal Pharmaceuticals LLC. (US)

Pfizer Inc. (US)

Zydus Cadila (India)

Dr. Reddy's Laboratories Ltd. (India)

Torrent Pharmaceuticals Ltd. (India)

Biocon (India)

Concept Medical (US)

Intas Pharmaceuticals Ltd (India)

Concord Biotech (India)

Livzon (China)

Actiza Pharmaceutical Private Limited (India)

Tiefenbacher API + Ingredients GmbH & Co. KG (Germany)

Delphis Pharmaceutical (India).

#### Market Segmentation

The Global Sirolimus Market Share, Demand provides the most up-to-date Pharmaceuticals industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

#### By Strength

5mg

1mg

2mg

1mg/mL

#### By Application

Organ Transplant Rejection

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Sirolimus Catheter Device  
Sirolimus Coated Balloons  
Others

By Drug Class

mTOR Inhibitors  
Selective Immunosuppressants

By Dosage

Injection  
Tablet  
Others

By Route of Administration

Oral  
Intravenous  
Others

By End-Users

Hospitals  
Specialty Clinics  
Homecare  
Others

Regions Coverd

North America

U.S.  
Canada

Europe

U.K.  
Germany  
France

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Spain  
Italy  
Russia  
Nordic  
Benelux  
Rest of Europe

APAC

China  
Korea  
Japan  
India  
Australia  
Singapore  
Taiwan  
South East Asia  
Rest of Asia-Pacific

Middle East and Africa

UAE  
Turkey  
Saudi Arabia  
South Africa  
Egypt  
Nigeria  
Rest of MEA

LATAM

Brazil  
Mexico  
Argentina  
Chile  
Colombia  
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

## **Table of Contents:**

- 1 Executive Summary
- 2 Research Scope & Segmentation
  - 2.1 Research Objectives
  - 2.2 Limitations & Assumptions
  - 2.3 Market Scope & Segmentation
  - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
  - 3.1 Emerging Regions / Countries
  - 3.2 Emerging Companies
  - 3.3 Emerging Applications / End Use
- 4 Market Trends
  - 4.1 Drivers
  - 4.2 Market Warning Factors
  - 4.3 Latest Macro Economic Indicators
  - 4.4 Geopolitical Impact
  - 4.5 Technology Factors
- 5 Market Assessment
  - 5.1 Porters Five Forces Analysis
  - 5.2 Value Chain Analysis
- 6 Global Sirolimus Market Size Analysis
  - 6.1 By Strength
    - 6.1.1 5mg
    - 6.1.2 1mg
    - 6.1.3 2mg
    - 6.1.4 1mg/mL
  - 6.2 By Application
    - 6.2.1 Organ Transplant Rejection
    - 6.2.2 Sirolimus Catheter Device
    - 6.2.3 Sirolimus Coated Balloons
    - 6.2.4 Others
  - 6.3 By Drug Class
    - 6.3.1 mTOR Inhibitors
    - 6.3.2 Selective Immunosuppressants
  - 6.4 By Dosage
    - 6.4.1 Injection
    - 6.4.2 Tablet
    - 6.4.3 Others
  - 6.5 By Route of Administration
    - 6.5.1 Oral
    - 6.5.2 Intravenous
    - 6.5.3 Others
  - 6.6 By End-Users
    - 6.6.1 Hospitals

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.6.2 Specialty Clinics
- 6.6.3 Homecare
- 6.6.4 Others
- 7 North America Market Analysis
  - 7.1 By Strength
    - 7.1.1 5mg
    - 7.1.2 1mg
    - 7.1.3 2mg
    - 7.1.4 1mg/mL
  - 7.2 By Application
    - 7.2.1 Organ Transplant Rejection
    - 7.2.2 Sirolimus Catheter Device
    - 7.2.3 Sirolimus Coated Balloons
    - 7.2.4 Others
  - 7.3 By Drug Class
    - 7.3.1 mTOR Inhibitors
    - 7.3.2 Selective Immunosuppressants
  - 7.4 By Dosage
    - 7.4.1 Injection
    - 7.4.2 Tablet
    - 7.4.3 Others
  - 7.5 By Route of Administration
    - 7.5.1 Oral
    - 7.5.2 Intravenous
    - 7.5.3 Others
  - 7.6 By End-Users
    - 7.6.1 Hospitals
    - 7.6.2 Specialty Clinics
    - 7.6.3 Homecare
    - 7.6.4 Others
  - 7.6 U.S.
  - 7.7 Canada
- 8 Europe Market Analysis
  - 8.1 By Strength
    - 8.1.1 5mg
    - 8.1.2 1mg
    - 8.1.3 2mg
    - 8.1.4 1mg/mL
  - 8.2 By Application
    - 8.2.1 Organ Transplant Rejection
    - 8.2.2 Sirolimus Catheter Device
    - 8.2.3 Sirolimus Coated Balloons
    - 8.2.4 Others
  - 8.3 By Drug Class
    - 8.3.1 mTOR Inhibitors
    - 8.3.2 Selective Immunosuppressants
  - 8.4 By Dosage

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.4.1 Injection
- 8.4.2 Tablet
- 8.4.3 Others
- 8.5 By Route of Administration
  - 8.5.1 Oral
  - 8.5.2 Intravenous
  - 8.5.3 Others
- 8.6 By End-Users
  - 8.6.1 Hospitals
  - 8.6.2 Specialty Clinics
  - 8.6.3 Homecare
  - 8.6.4 Others
- 8.6 U.K.
- 8.7 Germany
- 8.8 France
- 8.9 Spain
- 8.10 Italy
- 8.11 Russia
- 8.12 Nordic
- 8.13 Benelux
- 8.14 Rest of Europe
- 9 APAC Market Analysis
  - 9.1 By Strength
    - 9.1.1 5mg
    - 9.1.2 1mg
    - 9.1.3 2mg
    - 9.1.4 1mg/mL
  - 9.2 By Application
    - 9.2.1 Organ Transplant Rejection
    - 9.2.2 Sirolimus Catheter Device
    - 9.2.3 Sirolimus Coated Balloons
    - 9.2.4 Others
  - 9.3 By Drug Class
    - 9.3.1 mTOR Inhibitors
    - 9.3.2 Selective Immunosuppressants
  - 9.4 By Dosage
    - 9.4.1 Injection
    - 9.4.2 Tablet
    - 9.4.3 Others
  - 9.5 By Route of Administration
    - 9.5.1 Oral
    - 9.5.2 Intravenous
    - 9.5.3 Others
  - 9.6 By End-Users
    - 9.6.1 Hospitals
    - 9.6.2 Specialty Clinics
    - 9.6.3 Homecare

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.6.4 Others
- 9.6 China
- 9.7 Korea
- 9.8 Japan
- 9.9 India
- 9.10 Australia
- 9.11 Singapore
- 9.12 Taiwan
- 9.13 South East Asia
- 9.14 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
- 10.1 By Strength
  - 10.1.1 5mg
  - 10.1.2 1mg
  - 10.1.3 2mg
  - 10.1.4 1mg/mL
- 10.2 By Application
  - 10.2.1 Organ Transplant Rejection
  - 10.2.2 Sirolimus Catheter Device
  - 10.2.3 Sirolimus Coated Balloons
  - 10.2.4 Others
- 10.3 By Drug Class
  - 10.3.1 mTOR Inhibitors
  - 10.3.2 Selective Immunosuppressants
- 10.4 By Dosage
  - 10.4.1 Injection
  - 10.4.2 Tablet
  - 10.4.3 Others
- 10.5 By Route of Administration
  - 10.5.1 Oral
  - 10.5.2 Intravenous
  - 10.5.3 Others
- 10.6 By End-Users
  - 10.6.1 Hospitals
  - 10.6.2 Specialty Clinics
  - 10.6.3 Homecare
  - 10.6.4 Others
- 10.6 UAE
- 10.7 Turkey
- 10.8 Saudi Arabia
- 10.9 South Africa
- 10.10 Egypt
- 10.11 Nigeria
- 10.12 Rest of MEA
- 11 LATAM Market Analysis
- 11.1 By Strength
  - 11.1.1 5mg

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.1.2 1mg
- 11.1.3 2mg
- 11.1.4 1mg/mL
- 11.2 By Application
  - 11.2.1 Organ Transplant Rejection
  - 11.2.2 Sirolimus Catheter Device
  - 11.2.3 Sirolimus Coated Balloons
  - 11.2.4 Others
- 11.3 By Drug Class
  - 11.3.1 mTOR Inhibitors
  - 11.3.2 Selective Immunosuppressants
- 11.4 By Dosage
  - 11.4.1 Injection
  - 11.4.2 Tablet
  - 11.4.3 Others
- 11.5 By Route of Administration
  - 11.5.1 Oral
  - 11.5.2 Intravenous
  - 11.5.3 Others
- 11.6 By End-Users
  - 11.6.1 Hospitals
  - 11.6.2 Specialty Clinics
  - 11.6.3 Homecare
  - 11.6.4 Others
- 11.6 Brazil
- 11.7 Mexico
- 11.8 Argentina
- 11.9 Chile
- 11.10 Colombia
- 11.11 Rest of LATAM
- 12 Competitive Landscape
  - 12.1 Global Sirolimus Market Share By Players
  - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
  - 13.1 American International Industries (GIGI)
    - 13.1.1 Overview
    - 13.1.2 Business Information
    - 13.1.3 Revenue
    - 13.1.4 ASP
    - 13.1.5 Swot Analysis
    - 13.1.6 Recent Developments
  - 13.2 Apotex Inc. (Canada)
  - 13.3 and Amneal Pharmaceuticals LLC. (US)
  - 13.4 Pfizer Inc. (US)
  - 13.5 Zydus Cadila (India)
  - 13.6 Dr. Reddy's Laboratories Ltd. (India)
  - 13.7 Torrent Pharmaceuticals Ltd. (India)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.8 Biocon (India)
- 13.9 Concept Medical (US)
- 13.10 Intas Pharmaceuticals Ltd (India)
- 13.11 Concord Biotech (India)
- 13.12 Livzon (China)
- 13.13 Actiza Pharmaceutical Private Limited (India)
- 13.14 Tiefenbacher API + Ingredients GmbH & Co. KG (Germany)
- 13.15 Delphis Pharmaceutical (India).
- 14 Research Methodology
  - 14.1 Research Data
    - 14.1.1 Secondary Data
      - 14.1.1.1 Major secondary sources
      - 14.1.1.2 Key data from secondary sources
    - 14.1.2 Primary Data
      - 14.1.2.1 Key data from primary sources
      - 14.1.2.2 Breakdown of primaries
    - 14.1.3 Secondary And Primary Research
      - 14.1.3.1 Key industry insights
  - 14.2 Market Size Estimation
    - 14.2.1 Bottom-Up Approach
    - 14.2.2 Top-Down Approach
    - 14.2.3 Market Projection
  - 14.3 Research Assumptions
    - 14.3.1 Assumptions
  - 14.4 Limitations
  - 14.5 Risk Assessment
- 15 Appendix
  - 15.1 Discussion Guide
  - 15.2 Customization Options
  - 15.3 Related Reports
- 16 Disclaimer

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Sirolimus Market Size, Share & Trends Analysis Report By Strength (5mg, 1mg, 2mg, 1mg/mL), By Application (Organ Transplant Rejection, Sirolimus Catheter Device, Sirolimus Coated Balloons, Others), By Drug Class (mTOR Inhibitors, Selective Immunosuppressants), By Dosage (Injection, Tablet, Others), By Route of Administration (Oral, Intravenous, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031**

Market Report | 2024-03-19 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Job title\*

Company Name\*

Address\*

Zip Code\*

EU Vat / Tax ID / NIP number\*

City\*

Country\*

Date

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com